Drug Profile
Research programme: CXCR4 receptor antagonists - Proximagen
Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Biovitrum; Pharmacopeia
- Developer Proximagen
- Class Small molecules
- Mechanism of Action CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Glioblastoma
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Glioblastoma in United Kingdom
- 31 Dec 2019 Preclinical development is ongoing in United Kingdom
- 16 Jul 2016 No recent reports of development identified for preclinical development in Glioblastoma in United Kingdom